Journey Medical Corporation (DERM) Earnings History
Net Loss12 years of earnings data (2014–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Journey Medical Corporation (DERM) Earnings Overview
As of June 22, 2026, Journey Medical Corporation (DERM) reported trailing twelve-month net income of -$10M, reflecting +34.7% year-over-year growth. The company earned $-0.35 per diluted share over the past four quarters, with a net profit margin of -18.5%.
Looking at the long-term picture, DERM's historical earnings data spans multiple years. The company achieved its highest annual net income of $5M in fiscal 2020.
Journey Medical Corporation is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SKIN (-$6M net income, -3.2% margin), PRGO (-$1.82B net income, -33.5% margin), NVCR (-$173M net income, -20.8% margin), DERM has room to improve margins relative to the peer group. Compare DERM vs SKIN →
DERM Earnings vs Peers
Earnings metrics vs comparable public companies
DERM Historical Earnings Data (2014–2025)
12 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$11M | +22.1% | -$8M | $-0.47 | -18.5% | -13.2% |
| 2024 | -$15M | -280.8% | -$14M | $-0.72 | -26.1% | -24.4% |
| 2023 | -$4M | +87.0% | -$2M | $-0.21 | -4.9% | -2.6% |
| 2022 | -$30M | +32.7% | -$28M | $-1.69 | -40.2% | -37.4% |
| 2021 | -$44M | -932.7% | -$35M | $-2.54 | -69.7% | -55.2% |
| 2020 | $5M | +45.7% | $8M | $0.32 | 11.9% | 17.6% |
| 2019 | $4M | +101.6% | $5M | $0.22 | 10.4% | 15.1% |
| 2018 | -$222M | +26.9% | -$214M | $-5.27 | -523.3% | -505.4% |
| 2017 | -$303M | -240.4% | -$300M | $-7.48 | -6678.3% | -6613.7% |
| 2016 | -$89M | -13.6% | -$91M | $-2.70 | -394.4% | -401.3% |
| 2015 | -$78M | -146.0% | -$80M | $-2.93 | -1074.0% | -1092.7% |
| 2014 | -$32M | - | -$32M | $-1.29 | -436.6% | -434.2% |
Download Data
Export DERM earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
12+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
DERM — Frequently Asked Questions
Quick answers to the most common questions about buying DERM stock.
What is DERM earnings per share (EPS)?
DERM trailing twelve-month (TTM) diluted EPS is $-0.35, reflecting +34.7% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2014 to 2025 is available in the table on this page.
What is Journey Medical Corporation's net income?
Journey Medical Corporation (DERM) trailing twelve-month net income is $-10M as of 2025. Earnings grew +34.7% year-over-year.
Is DERM profitable?
DERM is not currently profitable on a TTM basis, reporting a net loss of $-10M. Net margin is -18.5%. Investors should monitor for a return to profitability.
What is DERM's earnings growth rate?
DERM compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2014 to 2025.
What are DERM's profit margins?
Journey Medical Corporation net profit margin is -18.5%, operating margin is -13.2%, and gross margin is +59.3%. Below-average margins reflect competitive or cost pressures. Return on Equity is -44.0%.
Is DERM growing earnings?
Yes, DERM earnings are accelerating — EPS growth of +34.7% exceeds the 5-year CAGR of N/A. TTM net income reached $-10M. Earnings momentum is strengthening.
What was DERM's best earnings year?
Journey Medical Corporation's highest annual net income on record is $5M, achieved in fiscal year 2020. Earnings history on this page spans 2014 to 2025 and includes all annual and quarterly figures.
What were DERM's earnings last quarter?
DERM's most recent reported quarter was Q1 2026. Net income was $-2M with diluted EPS of $-0.08. For a full breakdown of all quarters, see the quarterly earnings table on this page.